Oncologia D' Or Salvador, Salvador, Brazil.
Hospital Universitário de Brasília (UNB), Brasília, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil.
Clin Genitourin Cancer. 2024 Oct;22(5):102174. doi: 10.1016/j.clgc.2024.102174. Epub 2024 Jul 25.
Fibroblast growth factor receptor (FGFR) mutations and fusions are relevant biomarkers in metastatic urothelial carcinoma (mUC). However, the prevalence of genomic alterations and their impact on clinical outcomes in a Latin American population remains unknown. This study aimed to explore the prevalence of FGFR mutations and/or fusions in patients with mUC in Latin America (LATAM) and its association with clinicopathological characteristics, Bellmunt's prognostic model, and survival outcomes.
A multicenter retrospective cohort study from 2016 to 2019 of patients with mUC from several LACOG LATAM institutions. FGFR alterations were analyzed by real-time PCR and/or next-generation sequencing in tumor samples and clinicopathologic characteristics and survival outcomes data were collected. The prevalence of FGFR, patient characteristics, and treatment in real-world settings were summarized. Kaplan-Meier survival estimates and Cox regression analyses were used to evaluate the associations of FGFR mutation and/or fusion status with median overall survival (mOS), median time to treatment failure (mTTF), and clinicopathological characteristics.
In total, 222 patients were screened. Of these, 196 patients were considered eligible and were included in the analysis. FGFR mutations and/or fusions were found in 35 (17.9%) patients. There was no statistical difference in mOS and mTTF in FGFR-altered and non-altered patients (13.1 vs. 16.8 months, P = .20 and 3.9 vs. 4.1 months, P = .96, respectively). Bellmunt's prognostic model correctly predicted overall survival (P = .049).
This is the largest study evaluating the prevalence of FGFR alterations in patients with mUC in the LATAM population. FGFR alterations in mUC were found in 17.9% of the patients, and the presence of this biomarker was not associated with OS. We validated Bellmunt's prognostic model in this cohort.
成纤维细胞生长因子受体（FGFR）突变和融合是转移性尿路上皮癌（mUC）的相关生物标志物。然而，在拉丁美洲人群中，基因组改变的流行程度及其对临床结果的影响尚不清楚。本研究旨在探讨拉丁美洲（LATAM）mUC 患者中 FGFR 突变和/或融合的流行程度及其与临床病理特征、Bellmunt 预后模型和生存结果的关系。
这是一项来自 LACOG LATAM 多个机构的 2016 年至 2019 年的多中心回顾性队列研究，对 mUC 患者的肿瘤样本进行了实时 PCR 和/或下一代测序分析，以检测 FGFR 改变，并收集了临床病理特征和生存结局数据。总结了真实世界环境中 FGFR 的流行率、患者特征和治疗情况。使用 Kaplan-Meier 生存估计和 Cox 回归分析评估 FGFR 突变和/或融合状态与中位总生存期（mOS）、中位治疗失败时间（mTTF）和临床病理特征的关系。
共筛选了 222 例患者，其中 196 例符合条件并纳入分析。在这 196 例患者中，35 例（17.9%）患者发现 FGFR 突变和/或融合。FGFR 改变和未改变患者的 mOS 和 mTTF 无统计学差异（13.1 与 16.8 个月，P=0.20 和 3.9 与 4.1 个月，P=0.96）。Bellmunt 预后模型正确预测了总生存期（P=0.049）。
这是评估拉丁美洲人群 mUC 患者 FGFR 改变流行率的最大规模研究。在 mUC 患者中发现了 17.9%的 FGFR 改变，而该生物标志物的存在与 OS 无关。我们在该队列中验证了 Bellmunt 预后模型。
